The clinical significance of PCDH10 promoter methylation in patients with bladder transitional cell carcinoma

Urologia Internationalis

Volumn 90, Issue 2, 2013, Pages 219-224

  Lin, Ying Li ^a   Li, Zhi Gang ^b   Guan, Tong Yu ^a  

^a Xuzhou Tumor Hospital (Xuzhou Third People's Hospital)   (China)

^b General Hospital of CNPC in Jilin   (China)

Author keywords

Bladder cancer; Methylation; PCDH10

Indexed keywords

CADHERIN; MESSENGER RNA; PROTOCADHERIN 10; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CARCINOMA; BLADDER EPITHELIUM; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; TRANSITIONAL CELL CARCINOMA; TUMOR VOLUME;

AGED; CADHERINS; CARCINOMA, TRANSITIONAL CELL; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROMOTER REGIONS, GENETIC; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84874477182     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000345053     Document Type: Article

References (30)

1. Ploeg M, Aben KK, Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol 2009; 27: 289-293
2. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR: Recurrence and progression of disease in non-muscle-invasive bladder cancer: From epidemiology to treatment strategy. Eur Urol 2009; 56: 430-442
3. Jacobs BL, Lee CT, Montie JE: Bladder cancer in 2010: How far have we come? CA Cancer J Clin 2010; 60: 244-272
4. Morgan TM, Keegan KA, Clark PE: Bladder cancer. Curr Opin Oncol 2011; 23: 275-282
5. Herr HW, Dotan Z, Donat SM, Bajorin DF: Defining optimal therapy for muscle invasive bladder cancer. J Urol 2007; 177: 437-443
6. Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg MP, Lerner SP: Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: A contemporary series from the Bladder Cancer Research Consortium. J Urol 2006; 176: 2414-2422
7. Black PC, Dinney CP: Bladder cancer angiogenesis and metastasis -translation from murine model to clinical trial. Cancer Metastasis Rev 2007; 26: 623-634
8. Bolenz C, Lotan Y: Molecular biomarkers for urothelial carcinoma of the bladder: Challenges in clinical use. Nat Clin Pract Urol 2008; 5: 676-685
9. Vrooman OP, Witjes JA: Molecular markers for detection, surveillance and prognostication of bladder cancer. Int J Urol 2009; 16: 234-243
10. Lin Y, Sun G, Liu X, Chen Y, Zhang C: Clinical significance of T-cadherin tissue expression in patients with bladder transitional cell carcinoma. Urol Int 2011; 86: 340-345
11. Bertrand KC, Mack SC, Northcott PA, Garzia L, Dubuc A, Pfister SM, Rutka JT, Weiss WA, Taylor MD: PCDH10 is a candidate tumour suppressor gene in medulloblastoma. Childs Nerv Syst 2011; 27: 1243-1249
12. Narayan G, Freddy AJ, Xie D, Liyanage H, Clark L, Kisselev S, Un Kang J, Nandula SV, McGuinn C, Subramaniyam S, Alobeid B, Satwani P, Savage D, Bhagat G, Murty VV: Promoter methylation-mediated inactivation of PCDH10 in acute lymphoblastic leukemia contributes to chemotherapy resistance. Genes Chromosomes Cancer 2011; 50: 1043-1053
13. Li Z, Chim JC, Yang M, Ye J, Wong BC, Qiao L: Role of PCDH10 and its hypermethylation in human gastric cancer. Biochim Biophys Acta 2012; 1823: 298-305
14. Li Y, Yang ZS, Song JJ, Liu Q, Chen JB: Protocadherin-10 is involved in angiogenesis and methylation correlated with multiple myeloma. Int J Mol Med 2012; 29: 704-710
15. Li Z, Li W, Xie J, Wang Y, Tang A, Li X, Ye J, Gui Y, Cai Z: Epigenetic inactivation of PCDH10 in human prostate cancer cell lines. Cell Biol Int 2011; 35: 671-676
16. Oosterlinck W, Lobel B, Jakse G, Malmström PU, Stöckle M, Sternberg C: European Association of Urology (EAU) Working Group on Oncological Urology. Guidelines on bladder cancer. Eur Urol 2002; 41: 105-112
17. Ying J, Li H, Seng TJ, Langford C, Srivastava G, Tsao SW, Putti T, Murray P, Chan AT, Tao Q: Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene 2006; 25: 1070-1080
18. Wang KH, Liu HW, Lin SR, Ding DC, Chu TY: Field methylation silencing of the protocadherin 10 gene in cervical carcinogenesis as a potential specific diagnostic test from cervical scrapings. Cancer Sci 2009; 100: 2175-2180
19. Ying J, Gao Z, Li H, Srivastava G, Murray PG, Goh HK, Lim CY, Wang Y, Marafioti T, Mason DY, Ambinder RF, Chan AT, Tao Q: Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies. Br J Haematol 2007; 136: 829-832
20. Dudziec E, Goepel JR, Catto JW: Global epigenetic profiling in bladder cancer. Epigenomics 2011; 3: 35-45
21. Lin YL, Liu XQ, Li WP, Sun G, Zhang CT: Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma. Int Urol Nephrol 2012; 44: 111-117
22. Dehan P, Kustermans G, Guenin S, Horion J, Boniver J, Delvenne P: DNA methylation and cancer diagnosis: New methods and applications. Expert Rev Mol Diagn 2009; 9: 651-657
23. Esteller M, Corn PG, Baylin SB, Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225-3229
24. Kim SY, Yasuda S, Tanaka H, Yamagata K, Kim H: Non-clustered protocadherin. Cell Adh Migr 2011; 5: 97-105
25. Yagi T: Clustered protocadherin family. Dev Growth Differ 2008; 50: 131-140
26. Ding K, Su Y, Pang L, Lu Q, Wang Z, Zhang S, Zheng S, Mao J, Zhu Y: Inhibition of apoptosis by downregulation of hBex1, a novel mechanism, contributes to the chemoresistance of Bcr/Abl+ leukemic cells. Carcinogenesis 2009; 30: 35-42
27. Nakao S, Platek A, Hirano S, Takeichi M: Contact-dependent promotion of cell migration by the OL-protocadherin-Nap1 interaction. J Cell Biol 2008; 182: 395-410
28. Uemura M, Nakao S, Suzuki ST, Takeichi M, Hirano S: OL-Protocadherin is essential for growth of striatal axons and thalamocortical projections. Nat Neurosci 2007; 10: 1151-1159
29. Murakami T, Hijikata T, Matsukawa M, Ishikawa H, Yorifuji H: Zebrafish protocadherin 10 is involved in paraxial mesoderm development and somitogenesis. Dev Dyn 2006; 235: 506-514
30. Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, Tian LW, Wong YP, Tong JH, Ying JM, Jin H, To KF, Chan FK, Sung JJ: Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 2009; 136: 640-651